ID

24045

Beschrijving

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1); ODM derived from: https://clinicaltrials.gov/show/NCT00509236

Link

https://clinicaltrials.gov/show/NCT00509236

Trefwoorden

Versies (1)
  1. 23-07-17 23-07-17 -
Geüploaded op

23 juli 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Diabetes Mellitus, Type 2 NCT00509236

Engels

Eligibility Diabetes Mellitus, Type 2 NCT00509236

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
participant has t2dm.
Beschrijving

Diabetes Mellitus, Non-Insulin-Dependent

Datatype

boolean

Alias
UMLS CUI [1]
C0011860
participant is on dialysis on day of signing informed consent.
Beschrijving

Dialysis | Informed Consent

Datatype

boolean

Alias
UMLS CUI [1]
C0011946
UMLS CUI [2]
C0021430
participant is unlikely to conceive or uses acceptable methods of birth control: hormonal contraceptive, intrauterine device (iud), diaphragm with spermicide, contraceptive sponge, condom, or vasectomy.
Beschrijving

Pregnancy Unlikely | Contraceptive methods | Hormonal contraception | Intrauterine Devices | Vaginal contraceptive diaphragm | Vaginal Spermicides | Contraceptive Sponge | Condom | Vasectomy

Datatype

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0750558
UMLS CUI [2]
C0700589
UMLS CUI [3]
C2985296
UMLS CUI [4]
C0021900
UMLS CUI [5]
C0042241
UMLS CUI [6]
C0087145
UMLS CUI [7]
C0183461
UMLS CUI [8]
C0677582
UMLS CUI [9]
C0042387
participant has hemoglobin a1c ≥7% and ≤9% measured at or within 2 weeks prior to visit 4/week -2.
Beschrijving

Glycosylated hemoglobin A

Datatype

boolean

Alias
UMLS CUI [1]
C0019018
participant is ≥85% compliant with study medication during the single-blind placebo run-in (as determined by tablet/capsule count) and compliant with diet, exercise and other run-in treatments during the run-in period.
Beschrijving

Compliance behavior Percent Investigational New Drugs | Compliance behavior Diet | Compliance behavior Exercise | Compliance behavior Therapeutic procedure Run-in Period

Datatype

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439165
UMLS CUI [1,3]
C0013230
UMLS CUI [2,1]
C1321605
UMLS CUI [2,2]
C0012159
UMLS CUI [3,1]
C1321605
UMLS CUI [3,2]
C0015259
UMLS CUI [4,1]
C1321605
UMLS CUI [4,2]
C0087111
UMLS CUI [4,3]
C3274438
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
participant has a history of type 1 diabetes mellitus or a history of ketoacidosis.
Beschrijving

Diabetes Mellitus, Insulin-Dependent | Ketoacidosis

Datatype

boolean

Alias
UMLS CUI [1]
C0011854
UMLS CUI [2]
C0220982
participant is losing weight in a weight loss program and is not in the maintenance phase (defined as <2 kg weight loss in 2 months), or intends to be involved in weight loss intervention outside that prescribed by the study.
Beschrijving

Losing weight Weight Reduction Program | Maintenance Phase Absent | Weight loss Intervention intended

Datatype

boolean

Alias
UMLS CUI [1,1]
C1262477
UMLS CUI [1,2]
C3179079
UMLS CUI [2,1]
C0024501
UMLS CUI [2,2]
C0205390
UMLS CUI [2,3]
C0332197
UMLS CUI [3,1]
C1262477
UMLS CUI [3,2]
C0184661
UMLS CUI [3,3]
C1283828
participant has a clinically significant hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia).
Beschrijving

Hematological Disease | Aplastic Anemia | myeloproliferative syndrome | MYELODYSPLASTIC SYNDROME | Thrombocytopenia

Datatype

boolean

Alias
UMLS CUI [1]
C0018939
UMLS CUI [2]
C0002874
UMLS CUI [3]
C1443043
UMLS CUI [4]
C3463824
UMLS CUI [5]
C0040034
participant has cirrhosis or active liver disease.
Beschrijving

Liver Cirrhosis | Liver diseases

Datatype

boolean

Alias
UMLS CUI [1]
C0023890
UMLS CUI [2]
C0023895
participant has been on dialysis for < 6 months.
Beschrijving

Dialysis Duration

Datatype

boolean

Alias
UMLS CUI [1,1]
C0011946
UMLS CUI [1,2]
C0449238
participant has been diagnosed with a significant cardiovascular disorder and has new or worsening signs or symptoms of congestive heart failure within 3 months of signing informed consent.
Beschrijving

Cardiovascular Disease | Congestive heart failure Sign or Symptom New | Congestive heart failure Sign or Symptom Worsening

Datatype

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2,1]
C0018802
UMLS CUI [2,2]
C3540840
UMLS CUI [2,3]
C0205314
UMLS CUI [3,1]
C0018802
UMLS CUI [3,2]
C3540840
UMLS CUI [3,3]
C0332271
participant has severe active peripheral vascular disease.
Beschrijving

Peripheral Vascular Disease Severe

Datatype

boolean

Alias
UMLS CUI [1,1]
C0085096
UMLS CUI [1,2]
C0205082
participant has a history of malignancy ≤ 5 years prior to signing informed consent, or > 5 years without documentation of remission/cure.
Beschrijving

Malignant Neoplasms disease length | Remission Absent | Cure Absent

Datatype

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0872146
UMLS CUI [2,1]
C0687702
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C1880198
UMLS CUI [3,2]
C0332197
participant is under treatment for hyperthyroidism.
Beschrijving

Therapeutic procedure Hyperthyroidism

Datatype

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0020550
participant has a hypersensitivity or contraindication to glipizide.
Beschrijving

Hypersensitivity Glipizide | Medical contraindication Glipizide

Datatype

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0017642
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0017642
Terug naar het begin van de pagina

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT00509236

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
participant has t2dm.
boolean
C0011860 (UMLS CUI [1])
Dialysis | Informed Consent
Item
participant is on dialysis on day of signing informed consent.
boolean
C0011946 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
Pregnancy Unlikely | Contraceptive methods | Hormonal contraception | Intrauterine Devices | Vaginal contraceptive diaphragm | Vaginal Spermicides | Contraceptive Sponge | Condom | Vasectomy
Item
participant is unlikely to conceive or uses acceptable methods of birth control: hormonal contraceptive, intrauterine device (iud), diaphragm with spermicide, contraceptive sponge, condom, or vasectomy.
boolean
C0032961 (UMLS CUI [1,1])
C0750558 (UMLS CUI [1,2])
C0700589 (UMLS CUI [2])
C2985296 (UMLS CUI [3])
C0021900 (UMLS CUI [4])
C0042241 (UMLS CUI [5])
C0087145 (UMLS CUI [6])
C0183461 (UMLS CUI [7])
C0677582 (UMLS CUI [8])
C0042387 (UMLS CUI [9])
Glycosylated hemoglobin A
Item
participant has hemoglobin a1c ≥7% and ≤9% measured at or within 2 weeks prior to visit 4/week -2.
boolean
C0019018 (UMLS CUI [1])
Compliance behavior Percent Investigational New Drugs | Compliance behavior Diet | Compliance behavior Exercise | Compliance behavior Therapeutic procedure Run-in Period
Item
participant is ≥85% compliant with study medication during the single-blind placebo run-in (as determined by tablet/capsule count) and compliant with diet, exercise and other run-in treatments during the run-in period.
boolean
C1321605 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
C1321605 (UMLS CUI [2,1])
C0012159 (UMLS CUI [2,2])
C1321605 (UMLS CUI [3,1])
C0015259 (UMLS CUI [3,2])
C1321605 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C3274438 (UMLS CUI [4,3])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent | Ketoacidosis
Item
participant has a history of type 1 diabetes mellitus or a history of ketoacidosis.
boolean
C0011854 (UMLS CUI [1])
C0220982 (UMLS CUI [2])
Losing weight Weight Reduction Program | Maintenance Phase Absent | Weight loss Intervention intended
Item
participant is losing weight in a weight loss program and is not in the maintenance phase (defined as <2 kg weight loss in 2 months), or intends to be involved in weight loss intervention outside that prescribed by the study.
boolean
C1262477 (UMLS CUI [1,1])
C3179079 (UMLS CUI [1,2])
C0024501 (UMLS CUI [2,1])
C0205390 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C1262477 (UMLS CUI [3,1])
C0184661 (UMLS CUI [3,2])
C1283828 (UMLS CUI [3,3])
Hematological Disease | Aplastic Anemia | myeloproliferative syndrome | MYELODYSPLASTIC SYNDROME | Thrombocytopenia
Item
participant has a clinically significant hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia).
boolean
C0018939 (UMLS CUI [1])
C0002874 (UMLS CUI [2])
C1443043 (UMLS CUI [3])
C3463824 (UMLS CUI [4])
C0040034 (UMLS CUI [5])
Liver Cirrhosis | Liver diseases
Item
participant has cirrhosis or active liver disease.
boolean
C0023890 (UMLS CUI [1])
C0023895 (UMLS CUI [2])
Dialysis Duration
Item
participant has been on dialysis for < 6 months.
boolean
C0011946 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Cardiovascular Disease | Congestive heart failure Sign or Symptom New | Congestive heart failure Sign or Symptom Worsening
Item
participant has been diagnosed with a significant cardiovascular disorder and has new or worsening signs or symptoms of congestive heart failure within 3 months of signing informed consent.
boolean
C0007222 (UMLS CUI [1])
C0018802 (UMLS CUI [2,1])
C3540840 (UMLS CUI [2,2])
C0205314 (UMLS CUI [2,3])
C0018802 (UMLS CUI [3,1])
C3540840 (UMLS CUI [3,2])
C0332271 (UMLS CUI [3,3])
Peripheral Vascular Disease Severe
Item
participant has severe active peripheral vascular disease.
boolean
C0085096 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Malignant Neoplasms disease length | Remission Absent | Cure Absent
Item
participant has a history of malignancy ≤ 5 years prior to signing informed consent, or > 5 years without documentation of remission/cure.
boolean
C0006826 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0687702 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C1880198 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Therapeutic procedure Hyperthyroidism
Item
participant is under treatment for hyperthyroidism.
boolean
C0087111 (UMLS CUI [1,1])
C0020550 (UMLS CUI [1,2])
Hypersensitivity Glipizide | Medical contraindication Glipizide
Item
participant has a hypersensitivity or contraindication to glipizide.
boolean
C0020517 (UMLS CUI [1,1])
C0017642 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0017642 (UMLS CUI [2,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial